SPY299.08+3.64 1.23%
DIA250.25+5.37 2.19%
IXIC9,340.22+15.63 0.17%

Esperion Therapeutics Q1 EPS $(2.840) Beats $(3.290) Estimate, Sales $1.840M Beat $520.000K Estimate

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(2.840) per share which beat the analyst consensus estimate of $(3.290) by 13.68 percent. This is a 192.51 percent decrease over earnings of $3.070 per

Benzinga · 05/06/2020 20:28

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(2.840) per share which beat the analyst consensus estimate of $(3.290) by 13.68 percent. This is a 192.51 percent decrease over earnings of $3.070 per share from the same period last year. The company reported quarterly sales of $1.840 million which beat the analyst consensus estimate of $520.000 thousand by 253.85 percent. This is a 98.73 percent decrease over sales of $145.419 million the same period last year.